Antibodies to watch in 2018

mAbs

Volumn 10, Issue 2, 2018, Pages 183-203

  Kaplon, Hélène ^a   Reichert, Janice M ^b  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b Antibody Society   (United States)

Author keywords

antibody therapeutics; cancer; European Medicines Agency; Food and Drug Administration; immune mediated disorders

Indexed keywords

AIMOVIG; AVELUMAB; BENRALIZUMAB; BRODALUMAB; BROLUCIZUMAB; BUROSUMAB; CAPLACIZUMAB; CRIZANLIZUMAB; DUPILUMAB; DURVALUMAB; EMICIZUMAB; EPTINEZUMAB; ERENUMAB; EVENITY; FASENRA; FREMANEZUMAB; GALCANEZUMAB; GUSELKUMAB; HEMLIBRA; IBALIZUMAB; INOTUZUMAB OZOGAMICIN; LANADELUMAB; LUMICEF; MOGAMULIZUMAB; MONOCLONAL ANTIBODY; OCRELIZUMAB; PRO 140; RAVULIZUMAB; RISANKIZUMAB; ROMOSOZUMAB; SACITUZUMAB GOVITECAN; SARILUMAB; SATRALIZUMAB; TILDRAKIZUMAB; UNINDEXED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; ASTHMA; ATOPIC DERMATITIS; BLADDER CANCER; CLINICAL OUTCOME; CUTANEOUS T CELL LYMPHOMA; DRUG APPROVAL; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; EUROPEAN MEDICINES AGENCY; EUROPEAN UNION; FOOD AND DRUG ADMINISTRATION; HEMOPHILIA A; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MERKEL CELL CARCINOMA; MIGRAINE; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; NONHUMAN; OSTEOPOROSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; UNITED STATES; X LINKED HYPOPHOSPHATEMIC RICKETS; DRUG DEVELOPMENT; TRENDS;

ANTIBODIES, MONOCLONAL; DRUG DISCOVERY; HUMANS;

EID: 85040979948     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2018.1415671     Document Type: Article

References (86)

1. Reichert JM. Antibodies to watch in 2017. MAbs. 2016;9(2):167–81. doi:10.1080/19420862.2016.1269580.
2. Reichert JM. Antibodies to watch in 2016. MAbs. 2016;8(2):197–204. doi:10.1080/19420862.2015.1125583.
3. Reichert JM. Antibodies to watch in 2015. MAbs. 2015;7(1):1–8. doi:10.4161/19420862.2015.988944.
4. Reichert JM. Antibodies to watch in 2014: Mid-year update. MAbs. 2014;6(4):799–802. doi:10.4161/mabs.29282.
5. Reichert JM. Antibodies to watch in 2014. MAbs. 2014;6(1):5–14. doi:10.4161/mabs.27333.
6. Reichert JM. Antibodies to watch in 2013: Mid-year update. MAbs. 2013;5(4):513–7. doi:10.4161/mabs.24990.
7. Reichert JM. Which are the antibodies to watch in 2013? MAbs. 2013;5(1):1–4. doi:10.4161/mabs.22976.
8. Reichert JM. Which are the antibodies to watch in 2012? MAbs. 2012;4(1):1–3. doi:10.4161/mabs.4.1.18719.
9. Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs. 2011;3(1):76–99. doi:10.4161/mabs.3.1.13895.
10. Reichert JM. Antibodies to watch in 2010. MAbs. 2010;2(1):84–100. doi:10.4161/mabs.2.1.10677.
11. Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, Toth D, Langley RG, Cather J, Gottlieb AB, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175(2):273–86. doi:10.1111/bjd.14493.
12. Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, Papp K, Spelman L, Toth D, Kerdel F, et al. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med. 2015;373(14):1318–28. doi:10.1056/NEJMoa1503824.
13. Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbé C, Linette GP, Milella M, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17(10):1374–85. doi:10.1016/S1470-2045(16)30364-3.
14. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP. Two Phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–48.
15. Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Simpson EL, Papp KA, Hong HC, Rubel D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–303. doi:10.1016/S0140-6736(17)31191-1.
16. Regeneron, Inc. Regeneron and Sanofi announce positive dupilumab topline results from Phase 3 trial in uncontrolled persistent asthma. September 11, 2017 press release. http://investor.regeneron.com/releasedetail.cfm?releaseid = 1039754.
17. Emery P, Rigby W, Tak PP, Dörner T, Olech E, Martin C, Millar L, Travers H, Fisheleva E. Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program. PLoS One. 2014 Feb 3;9(2):e87379. doi:10.1371/journal.pone.0087379.
18. Mysler EF, Spindler AJ, Guzman R, Bijl M, Jayne D, Furie RA, Houssiau FA, Drappa J, Close D, Maciuca R, et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum. 2013;65(9):2368–79. doi:10.1002/art.38037.
19. Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221–34. doi:10.1056/NEJMoa1601277.
20. Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376(3):209–20. doi:10.1056/NEJMoa1606468.
21. Powles T, O'Donnell PH, Massard C, Arkenau HT, Friedlander TW, Hoimes CJ, Lee JL, Ong M, Sridhar SS, Vogelzang NJ, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: Updated resultsfFrom a Phase 1/2 open-label study. JAMA Oncol. 2017;3(9):e172411. doi:10.1001/jamaoncol.2017.2411.
22. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med. 2017;377(20):1919–29. doi:10.1056/NEJMoa1709937.
23. Regeneron. Regeneron and Sanofi announce FDA approval of Kevzara® (sarilumab) for the treatment of moderately to severely active rheumatoid arthritis in adult patients. May 22, 2017 press release. http://investor.regeneron.com/releaseDetail.cfm?releaseid=1027419.
24. Regeneron. Regeneron and Sanofi announce approval of Kevzara® (sarilumab) to treat adult patients with moderately to severely active rheumatoid arthritis in the European Union. June 27, 2017. http://investor.regeneron.com/releasedetail.cfm?releaseid=1031395.
25. Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, Li S, Kimball AB. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–17. doi:10.1016/j.jaad.2016.11.041.
26. Nakamura M, Lee K, Jeon C, Sekhon S, Afifi L, Yan D, Lee K, Bhutani T. Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials. Dermatol Ther (Heidelb). 2017;7(3):281–92. doi:10.1007/s13555-017-0187-0.
27. Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418–31. doi:10.1016/j.jaad.2016.11.042.
28. Langley RG, Tsai TF, Flavin S, Song M, Randazzo B, Wasfi Y, Jiang J, Li S, Puig L. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2017. doi:10.1111/bjd.15750.
29. Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, Gökbuget N, O'Brien S, Wang K, Wang T, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740–53. doi:10.1056/NEJMoa1509277.
30. Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkström V, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–27. doi:10.1016/S0140-6736(16)31324-1.
31. FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–41. doi:10.1016/S0140-6736(16)31322-8.
32. Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, Barker P, Sproule S, Ponnarambil S, Goldman M,; ZONDA Trial Investigators. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448–58. doi:10.1056/NEJMoa1703501.
33. Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377(9):809–18. doi:10.1056/NEJMoa1703068.
34. Theratechnologies Inc. Theratechnologies announces 48-week efficacy and safety results for ibalizumab presented at IDWeek 2017™. October 4, 2017 press release. https://theratechnologies.s3.amazonaws.com/prod/media/nr-th-10042017-en.pdf
35. Ultragenyx Pharmaceutical Inc., Kyowa Hakko Kirin Co., Ltd., Kyowa Kirin International PLC. Ultragenyx, Kyowa Hakko Kirin and Kyowa Kirin International Announce Positive 24-Week Data from Adult Phase 3 Study of Burosumab (KRN23) in X-Linked Hypophosphatemia. April 18, 2017 press release. http://ir.ultragenyx.com/releasedetail.cfm?releaseid=1021735.
36. Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Thaçi D, Nograles K, Mehta A, Cichanowitz N, Li Q, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390(10091):276–88. doi:10.1016/S0140-6736(17)31279-5.
37. Ablynx. Ablynx announces positive topline results from the Phase III HERCULES study of caplacizumab for the treatment of acquired TTP. October 2, 2017 press release. http://hugin.info/137912/R/2138418/818605.pdf.
38. Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, Sapra S, Picard H, Mikol D, Lenz RA. A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med. 2017;377:2123–32. doi:10.1056/NEJMoa1705848.
39. Amgen. FDA accepts biologics license application for Aimovig™ (erenumab). July 20, 2017 press release. https://www.amgen.com/media/news-releases/2017/07/fda-accepts-biologics-license-application-for-aimovig-erenumab/.
40. Teva Pharmaceutical Industries Ltd. Teva announces submission of biologics license application for fremanezumab to the U.S. FDA. October 17, 2017 press release. http://www.tevapharm.com/news/teva_announces_submission_of_biologics_license_application_for_fremanezumab_to_the_u_s_fda_10_17.aspx.
41. Teva Pharmaceutical Industries Ltd. Teva's fremanezumab meets all primary & secondary endpoints across both monthly and quarterly dosing regimens in phase iii study in episodic migraine prevention. June 7, 2017 press release. http://www.tevapharm.com/news/teva_s_fremanezumab_meets_all_primary_secondary_endpoints_across_both_monthly_and_quarterly_dosing_regimens_in_phase_iii_study_in_episodic_migraine_prevention_06_17.aspx.
42. Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadbsy PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E. Fremanezumab for the Preventive Treatment of Chronic Migraine. N Engl J Med. 2017;377:2113–22, doi:10.1056/NEJMoa1709038.
43. Teva Pharmaceutical Industries Ltd. Teva announces positive results for phase iii study of fremanezumab for the prevention of chronic Migraine. May 31, 2017 press release. http://www.tevapharm.com/news/teva_announces_positive_results_for_phase_iii_study_of_fremanezumab_for_the_prevention_of_chronic_migraine_05_17.aspx
44. Eli Lilly and Company. Q3 2017 Earnings. October 24, 2017. http://files.shareholder.com/downloads/LLY/5243055213x0x960639/50A36D58-6F7B-4AF7-9A85-7FB924C59323/Q3_2017_Slides.pdf.
45. Eli Lilly and Company. Lilly's galcanezumab significantly reduces number of migraine headache days for patients with migraine: new results presented at AHS. June 10, 2017 press release. https://investor.lilly.com/releasedetail.cfm?releaseid=1029791.
46. Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1417–27. doi:10.1056/NEJMoa1708322.
47. Kyowa Hakko Kirin Co., Ltd. Kyowa Hakko Kirin announces marketing authorisation application for mogamulizumab validated by European Medicines Agency. October 27, 2017 press release. http://www.kyowa-kirin.com/news_releases/2017/pdf/e20171027_01.pdf.
48. Kim YH, Bagot M, Eradat HA, Carson KR, Greer JP, Kim EJ, Kuzel T, Hughey LC, Poligone B, Lansigan F, et al. Phase 3 study of anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat in relapsed or refractory cutaneous T-cell lymphoma (CTCL). J Clin Oncol. 2014:32(15_suppl):TPS8623–3. http://ascopubs.org/doi/abs/10.1200/jco.2014.32.15_suppl.tps8623.
49. Ornskov F, Mayer H. Shire reports positive topline Phase 3 results for lanadelumab (SHP643) in patients with hereditary angioedema (HAE). May 18, 2017. http://investors.shire.com/∼/media/Files/S/Shire-IR/presentations-webcast/year-2017/shire-investor-presentation-2017-05-18.pdf.
50. Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, Guthrie TH, Knight-Madden J, Alvarez OA, Gordeuk VR, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376(5):429–39. doi:10.1056/NEJMoa1611770.
51. Roeth A, Rottinghaus ST, Hill A, Kim JS, Schrezenmeier H, Jang JH, Szer J, Aguzzi R, Bachman ES, Damokosh AI, et al. Optimization of dose regimen for ALXN1210, a novel complement c5 inhibitor, in patients with paroxysmal nocturnal hemoglobinuria (PNH): Results of 2 Phase 1/2 Studies. 59th American Society of Hematology Annual Meeting & Exposition, December9–12, 2017, Atlanta. Abstract 3482. https://ash.confex.com/ash/2017/webprogram/Paper100715.html.
52. Alder BioPharmaceuticals. Alder BioPharmaceuticals announces positive eptinezumab Phase 3 results for prevention of frequent episodic migraine. June 27, 2017 press release. http://investor.alderbio.com/releasedetail.cfm?releaseid=1031418.
53. AbbVie. Risankizumab meets all co-primary and ranked secondary endpoints, achieving significantly greater efficacy versus standard biologic therapies in three pivotal Phase 3 psoriasis studies. October 26, 2017 press release. https://news.abbvie.com/news/risankizumab-meets-all-co-primary-and-ranked-secondary-endpoints-achieving-significantly-greater-efficacy-versus-standard-biologic-therapies-in-three-pivotal-phase-3-psoriasis-studies.htm.
54. Novartis. Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval. June 20, 2017 press release. https://www.novartis.com/news/media-releases/novartis-rth258-brolucizumab-demonstrates-robust-visual-gains-namd-patients.
55. Novartis. Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness. November 10, 2018 press release. https://www.novartis.com/news/media-releases/novartis-brolucizumab-rth258-demonstrates-superiority-versus-aflibercept-key.
56. CytoDyn. CytoDyn provides update on PRO 140 combination therapy pivotal trial in HIV patients following constructive meeting with FDA. August 21, 2017 press release. https://www.cytodyn.com/media/press-releases/detail/267/cytodyn-provides-update-on-pro-140-combination-therapy.
57. Gertz MA, Landau H, Comenzo RL, Seldin D, Weiss B, Zonder J, Merlini G, Schönland S, Walling J, Kinney GG, et al. First-in-human Phase I/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction. J Clin Oncol. 2016;34(10):1097–103. doi:10.1200/JCO.2015.63.6530.
58. Lasser R, Scheltens P, Dubois B, Nikolcheva T, Retout S, Volz D, Csilla C, Boada M. Efficacy, Safety and Biomarker Data from SCarlet RoAD–A global Phase 3 study of gantenerumab in patients with prodromal AD (S1.002). Neurology. 2016;86:Supplement S1.002.
59. MorphoSys. MorphoSys partner to start new Phase 3 clinical trials with gantenerumab in Alzheimer's disease. March 6, 2017 press release. https://www.morphosys.com/media-investors/media-center/morphosys-partner-to-start-new-phase-3-clinical-trials-with.
60. Peng L, Oganesyan V, Wu H, Dall'Acqua WF, Damschroder MM. Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibody. MAbs. 2015;7(2):428–39. doi:10.1080/19420862.2015.1007810.
61. Furie R, Khamashta M, Merrill JT, Werth VP, Kalunian K, Brohawn P, Illei GG, Drappa J, Wang L, Yoo S,; CD1013 Study Investigators. Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 2017;69(2):376–86. doi:10.1002/art.39962.
62. Immunomedics, Inc. Immunomedics announces first quarter fiscal 2018 results and provides corporate update. November 9, 2017 press release. http://www.immunomedics.com/pdfs/news/2017/pr11092017a.pdf.
63. Immunomedics, Inc. Immunomedics announces presentations and investor event at the 2017 San Antonio Breast Cancer Symposium. November 13, 2017 press release. http://www.immunomedics.com/pdfs/news/2017/pr11132017.pdf.
64. Bardia A, Vahdat LT, Diamond J, Kalinsky K, O'Shaughnessy J, Moroose RL, Isakoff SJ, Tolaney SM, Santin AD, Abramson V, et al. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate, as ≥3rd-line therapeutic option for patients with relapsed/refractory metastatic triple-negative breast cancer (mTNBC): efficacy results. 2017 San Antonio Breast Cancer Symposium. San Antonio, TX, December6, 2017. http://www.abstracts2view.com/sabcs/.
65. Bardia A, Rugo HS, Horne H, Wegener WA, Goldenberg DM, O'Shaughnessy J. A phase III, randomized trial of sacituzumab govitecan (IMMU-132) vs treatment of physician choice (TPC) for metastatic triple-negative breast cancer (mTNBC). 2017 San Antonio Breast Cancer Symposium. San Antonio, TX, December7, 2017. http://www.abstracts2view.com/sabcs/.
66. Papadopoulos K, Owonikoko T, Johnson M, Braňa I, Martin MG, Perez R, Moreno V, Salama A, Calvo E, Yee N, et al. REGN2810, A human anti-PD-1 monoclonal antibody, for patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Initial safety and efficacy. American Society of Clinical Oncology, 2017. http://files.shareholder.com/downloads/REGN/4776160898x0x945383/DB74E772-C8CA-43BC-AD1C-F0B7FFA2CCC4/Regeneron_ASCO_2017_Presentation.pdf.
67. TG Therapeutics. TG Therapeutics announces positive data from Phase 3 GENUINE trial of TG-1101 in combination with ibrutinib in patients with high risk chronic lymphocytic leukemia at the 53rd Annual Meeting of the American Society of Clinical Oncology. June 4, 2017 press release. http://ir.tgtherapeutics.com/releasedetail.cfm?releaseid=1028913
68. Sharman JP, Brander DM, Mato A, Kambhampati S, Burke JM, Lansigan F, Schreeder MT, Lunin SD, Ghosh N, Zweibach A, et al. Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE Phase 3 study. American Society of Clinical Oncology Annual Meeting (ASCO). 2017-06-03 Abstract 7504. http://www.tgtherapeutics.com/ASCO%202017%20Sharman%20Final.pdf.
69. AstraZeneca. Imfinzi plus tremelimumab combination did not meet a primary endpoint of progression-free survival compared to chemotherapy. July 17, 2017 press release. https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-reports-initial-results-from-the-ongoing-mystic-trial-in-stage-iv-lung-cancer-27072017.html.
70. Peters S, Antonia S, Goldberg SB, Heymach JV, Kim ES, Nakagawa K, Papadimitrakopoulou V, Mukhopadhyay P, McIntosh S, Rizvi NA. MYSTIC: a global, Phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC. J Thorac Oncol. 2016;11(4 Suppl):S139–40. doi:10.1016/S1556-0864(16)30300-8.
71. Planchard D, Yokoi T, McCleod MJ, Fischer JR, Kim YC, Ballas M, Shi K, Soria JC. A Phase III study of durvalumab (MEDI4736) with or without tremelimumab for previously treated patients with advanced NSCLC: Rationale and protocol design of the ARCTIC study. Clin Lung Cancer. 2016;17(3):232–236.e1. doi:10.1016/j.cllc.2016.03.003.
72. Mok T, Schmid P, Aren O, Arrieta O, Gottfried M, Jazieh AR, Ramlau R, Timcheva K, Martin C, McIntosh S. NEPTUNE: A global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy versus standard of care (SoC) platinum-based chemotherapy in the first-line treatment of patients (pts) with advanced or metastatic NSCLC. J Thorac Oncol. 2016;11(4 Suppl):S140–1. doi:10.1016/S1556-0864(16)30301-X.
73. Licitra L, Even C, Haddad R, Tahara M, Goswami T, Franks A, Emeribe U, Jarkowski A, Melillo G, Ferris RL. Phase 3 study of durvalumab (MEDI4736) alone or in combination with tremelimumab versus standard of care (SoC) in platinum-resistant recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): EAGLE. Ann Oncol. 1 December 2015;26(suppl_9):ix101. doi:10.1093/annonc/mdv527.28.
74. Seiwert TY, Weiss J, Baxi SS, Ahn M-J, Fayette J, Gillison ML. A phase 3, randomized, open-label study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC; EXTREME regimen) in recurrent/metastatic (R/M) SCCHN: KESTREL. J Clin Oncol 2016;34(15_suppl):TPS6101. http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.TPS6101. doi:10.1200/JCO.2016.34.15_suppl.TPS6101.
75. Park SH, Castellano D, Petrylak DP, Galsky MD, van der Heijden MS, Loriot Y, Ogawa O, Su W, Huang W, Levin W, et al. DANUBE: A Phase 3 randomised study of first-line durvalumab (MEDI4736) ± tremelimumab vs standard of care chemotherapy in patients with Stage IV urothelial carcinoma. http://oncologypro.esmo.org/Meeting-Resources/ESMO-Asia-2016-Congress/DANUBE-A-Phase-3-randomised-study-of-first-line-durvalumab-MEDI4736-tremelimumab-vs-standard-of-care-SoC-chemotherapy-CT-in-patients-pts-with-Stage-IV-urothelial-carcinoma-UC.
76. Richardson PG, Attal M, San Miguel J, Campana F, Le-Guennec S, Hui A-M. A phase III, randomized, open-label study of isatuximab (SAR650984) plus pomalidomide (Pom) and dexamethasone (Dex) versus Pom and Dex in relapsed/refractory multiple myeloma. J Clin Oncol 2017;35(15_suppl):TPS8057. doi:10.1200/JCO.2017.35.15_suppl.TPS8057.
77. Theuer CP, Myszka D, Sherwood S, Incardona F, Haughey D, Benedict S, Real S, Adams B, Leigh B, Seon BK. Preclinical pharmacokinetic & pharmacodynamic data for TRC105 (anti-endoglin antibody) are consistent with clinical activity observed at low doses in patients with advanced cancer. American Association for Cancer Research 2009, Abstract Number: 1237. http://www.traconpharma.com/pdfs/105.pdf.
78. Jones RL, Attia S, Mehta CR, Liu L, Sankhala KK, Robinson SI, Ravi V, Penel N, Stacchiotti S, Tap WD, et al. TAPPAS: An adaptive enrichment Phase 3 Trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma. ASCO 2017 Abstract # TPS11081. http://www.traconpharma.com/pdfs/ASCO_Poster_FINAL.pdf.
79. Liu SY, Wu YL. Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China. J Hematol Oncol. 2017;10(1):136. doi:10.1186/s13045-017-0506-z.
80. ImmunoGen. ImmunoGen announces new clinical data with mirvetuximab soravtansine in ovarian cancer to be presented at 2017 ASCO annual meeting. May 17, 2017 press release. http://investor.immunogen.com/releasedetail.cfm?releaseid=1026885.
81. Philogen. Philogen announces authorization from FDA of a pivotal registration trial in USA for the treatment of resectable melanoma. October 12, 2017 press release. http://www.philogen.com/media/all_news/PR_Daromun_FDA.pdf.
82. European Medicines Agency. Questions and answers: Refusal of the marketing authorization for human IgG1 monoclonal antibody specific for human interleukin-1 alpha XBiotech: Outcome of re-examination. EMA/609151/2017, EMEA/H/C/004388; September 15, 2017. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/004388/WC500228075.pdf.
83. XBiotech. XBiotech announces first patient in study evaluating MABp1 in combination with Onivyde® and 5-fluorouracil/folinic acid for the treatment of pancreatic cancer. October 18, 2017 press release. http://investors.xbiotech.com/phoenix.zhtml?c=253990& =irol-newsArticle&ID=2309535.
84. Merrimack Pharmaceuticals, Inc. Merrimack stops the Phase 2 HERMIONE trial of MM-302 in HER2-positive metastatic breast cancer patients. December 21, 2016 press release. http://investors.merrimack.com/news-releases/news-release-details/merrimack-stops-phase-2-hermione-trial-mm-302-her2-positive.
85. Seattle Genetics, Inc. Seattle Genetics discontinues phase 3 CASCADE trial of vadastuximab talirine (SGN-CD33A) in frontline acute myeloid leukemia. June 19, 2017 press release. http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=2281531.
86. Regeneron Pharmaceuticals, Inc. Regeneron to discontinue development of suptavumab for respiratory syncytial virus. August 14, 2017 press release. http://investor.regeneron.com/releaseDetail.cfm?releaseid=1037184.